Autoimmune hypophysitis

A 82-year-old male patient with metastatic lung adenocarcinoma presented to the outpatient clinic at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) in April, 2015 with worsening fatigue, headache, dizziness, blurry vision, and nausea. Immune checkpoint inhibitors such as anti-C...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The lancet oncology Ročník 19; číslo 2; s. e123
Hlavní autoři:	Ileana-Dumbrava, Ecaterina, Subbiah, Vivek
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 01.02.2018 Elsevier Limited
Témata:	Adenocarcinoma of Lung - drug therapy Adenocarcinoma of Lung - pathology Adrenal Cortex Hormones - therapeutic use Adrenal glands Aged, 80 and over Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Autoimmune Hypophysitis - diagnostic imaging Autoimmune Hypophysitis - drug therapy Autoimmune Hypophysitis - etiology Cancer Follow-Up Studies Hormones Humans Immune checkpoint inhibitors Ipilimumab - adverse effects Ipilimumab - therapeutic use Lung cancer Magnetic Resonance Imaging - methods Male Metastasis PD-L1 protein Pituitary Gland - diagnostic imaging Pituitary Gland - pathology Rare Diseases Risk Assessment Severity of Illness Index Thyroid gland Treatment Outcome United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	A 82-year-old male patient with metastatic lung adenocarcinoma presented to the outpatient clinic at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) in April, 2015 with worsening fatigue, headache, dizziness, blurry vision, and nausea. Immune checkpoint inhibitors such as anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibodies are US FDA and European Medicines Agency-approved treatments for several tumour types, including non-small-cell lung cancer, and are emerging as a standard of care.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Case Study-2 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	1470-2045 1474-5488 1474-5488
DOI:	10.1016/S1470-2045(17)30577-6